# Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma

> **NCT04072679** · PHASE1 · COMPLETED · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 50 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sintilimab+IBI305

## Key facts

- **NCT ID:** NCT04072679
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-11
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-11-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2021-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072679, "Safety and Efficacy Study of Sintilimab Combined With IBI305 in Patients With Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04072679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*